Ireland’s Chanelle is aiming at US liquids

Chanelle Pharma, “Ireland’s largest manufacturer of generic pharmaceuticals”, is spending €11 million (US$13 million) on a dedicated facility to produce liquid formulations for the US market. The plant, which is designed to comply with both US Food and Drug Administration (FDA) and European quality standards, forms part of an overall €86 million investment program that the firm has just unveiled.

Chanelle Pharma, “Ireland’s largest manufacturer of generic pharmaceuticals”, is spending €11 million (US$13 million) on a dedicated facility to produce liquid formulations for the US market. The plant, which is designed to comply with both US Food and Drug Administration (FDA) and European quality standards, forms part of an overall €86 million investment program that the firm has just unveiled.

Founder and managing director Michael Burke said Chanelle was picking up the pace of investment, having already since 2016 spent...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Manufacturing

More from Business